

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067921 A1

(51) International Patent Classification⁷: A61K 31/366,
31/40, 31/045, A61P 3/00

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(21) International Application Number:
PCT/IN2005/000024

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 19 January 2005 (19.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99/DEL/2004 20 January 2004 (20.01.2004) IN

(71) Applicant (for all designated States except US):
PANACEA BIOTEC LTD., [IN/IN]; B-1 Extn./A-27, Mohan
Co-Operative Industrial Estate, Mathura Road,
New Delhi - 110 044 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JAIN, Rajesh
[IN/IN]; Panacea Biotec Ltd, B-1 Extn./A-27, Mohan
Co-Operative Industrial Estate, Mathura Road, New
Delhi - 110 044 (IN). JINDAL, Kour, Chand [IN/IN];
Panacea Biotec Ltd, B-1 Extn./A-27, Mohan Co-Operative
Industrial Estate, Mathura Road, New Delhi - 110 044
(IN). SINGH, Sukhjeet [IN/IN]; Panacea Biotec Ltd,
B-1 Extn./A-27, Mohan Co-Operative Industrial Estate,
Mathura Road, New Delhi - 110 044 (IN).

(74) Agent: GUPTA, Bhartee; Panacea Biotec Ltd, B-1
Extn./A-27, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi - 110 044 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

(48) Date of publication of this corrected version:
3 November 2005

(15) Information about Correction:

see PCT Gazette No. 44/2005 of 3 November 2005, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING HIGHER PRIMARY ALIPHATIC ALCOHOLS AND HMG
COA REDUCTASE INHIBITOR AND PROCESS OF PREPARATION THEREOF

(57) Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39)
carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and
phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with
pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of
treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

BEST AVAILABLE COPY

WO 2005/067921 A1